Pediatric Oncology

📚 02 Pediatric Superspecialities • 🎯 177 High-Yield MCQs • Nelson 22nd Edition Standard

Pediatric Hematology & Oncology: Leukemias, Lymphomas, and Solid Tumors

  • Pediatric AML Induction and Consolidation Protocol: ((PONC001)): Standard treatment relies strictly on intensive chemotherapy blocks using cytarabine and anthracycline induction followed by high-dose cytarabine consolidation, and stem cell transplantation for high-risk cases. Maintenance therapy with oral mercaptopurine and methotrexate is strictly a hallmark of ALL protocols and not used in AML.
  • Favorable Cytogenetics in Pediatric AML: ((PONC002)): The translocation t(8;21)(q22;q22) is a favorable prognostic marker (frequently linked with AML-M2), conferring better survival and chemotherapy response. In contrast, monosomy 7 and FLT3-ITD mutations are adverse markers carrying high relapse rates and poor outcomes.
  • Inversion 16 in Pediatric AML: ((PONC028)): The inv(16)(p13q22) abnormality yields the CBFB-MYH11 fusion, presenting as acute myelomonocytic leukemia with abnormal eosinophils containing dysplastic basophilic granules (a favorable-risk category).
  • Accelerated Phase of CML: ((PONC003)): Defined by 10–19% blasts in blood or marrow, persistent/progressive splenomegaly, or cytogenetic evolution despite therapy. (Chronic phase features <10% blasts and <20% basophils).
  • Juvenile Myelomonocytic Leukemia (JMML): ((PONC004)): A rare myeloproliferative/myelodysplastic overlap disorder seen in children <4 years old, classically characterized by persistent monocytosis, organomegaly, and absence of BCR-ABL1 (frequently driven by RAS pathway mutations).
  • Infant Acute Lymphoblastic Leukemia (ALL): ((PONC014)): Features aggressive disease with B-lineage immunophenotype, absent CD10, hyperleukocytosis, and high prevalence of KMT2A (MLL) rearrangements at 11q23 (such as t(4;11)(q21;q23) – MLL-AF4). The highest risk group constitutes infants <6 months old with a leukocyte count ≥300,000/µL.
  • Pharmacogenetics of ALL Maintenance Therapy: ((PONC015)): Frequent mucositis and myelosuppression during 6-mercaptopurine maintenance necessitate pharmacogenetic testing of TPMT and NUDT15 genes to identify variant alleles causing impaired drug metabolism and severe toxicity.
  • CNS Prophylaxis in Pediatric ALL and NHL: ((PONC007)): The cornerstone of modern CNS prophylaxis is intrathecal chemotherapy (e.g., methotrexate, cytarabine, hydrocortisone), effectively avoiding the long-term neurocognitive and endocrine sequelae of cranial irradiation.
  • Favorable vs. Adverse Prognostic Factors in B-ALL: ((PONC017)): - Favorable markers: Age 1–10 years, WBC <50,000/µL, and t(12;21)(p13;q22) (ETV6-RUNX1). The TCF3-PBX1 translocation (t(1;19)) also carries a favorable risk profile. - Adverse markers: Age <1 year, hyperleukocytosis (WBC >50k), KMT2A rearrangement, and IKZF1 deletion (which overrides baseline favorable features).
  • Constitutional Predisposition to ALL: ((PONC025)): A constitutional Robertsonian translocation rob(15;21)(q10;q10) is an established inherited susceptibility factor predisposing to childhood ALL via secondary leukemogenic events on chromosome 21.
  • Transient Abnormal Myelopoiesis (TAM) in Down Syndrome: ((PONC029)): Neonates with Down syndrome may develop transient myeloproliferative disease driven by acquired GATA1 mutations. While it typically resolves spontaneously by 3 months, persistence of abnormal blasts detected by flow cytometry predicts a ~20–30% risk of developing overt myeloid leukemia of Down syndrome (often acute megakaryoblastic leukemia) within the first 1–5 years of life. --- ### Pediatric Lymphomas
  • Hodgkin Lymphoma Histologic Subtypes: ((PONC005)): Nodular sclerosis is the most frequent subtype in children and adolescents (especially females), classically presenting with mediastinal lymphadenopathy and an overall favorable prognosis.
  • Frontline Therapy for Pediatric Hodgkin Lymphoma: ((PONC006)): Standard management involves risk-adapted combination chemotherapy (e.g., ABVD, OEPA) with or without low-dose involved-field radiation, yielding cure rates >90%.
  • Prognostic Factors in Hodgkin Lymphoma: ((PONC033)): While Reed-Sternberg cells drive the disease, a microenvironment with reactive eosinophilic infiltration and high IL-6/macrophage production portends an unfavorable prognosis.
  • Relapsed Hodgkin Lymphoma Salvage: ((PONC034)): Early relapse (<12 months from diagnosis) carries a poor prognosis and requires definitive salvage via myeloablative chemotherapy followed by autologous stem cell transplantation.
  • Non-Hodgkin Lymphoma Cytogenetics: ((PONC008)): Burkitt lymphoma is defined by translocations moving the MYC oncogene on chromosome 8 to immunoglobulin heavy chain loci on chromosome 14 (t(8;14)), driving uncontrolled proliferation. MYC-negative Burkitt-like lymphomas frequently feature recurrent 11q abnormalities ((PONC035)). --- ### Solid Tumors of Childhood
  • Neuroblastoma Prognostication: ((PONC009)): Age >18 months at diagnosis is the strongest adverse prognostic factor, with older children presenting with metastatic (Stage 4) disease having significantly lower survival.
  • Retinoblastoma Management: ((PONC010)): Systemic chemotherapy combined with local focal therapies (chemoreduction) has largely minimized the need for external beam radiotherapy, reducing secondary germline RB1 malignancy risks.
  • Pediatric Brain Tumors: ((PONC011)): - Pilocytic astrocytoma is the most common pediatric brain tumor, frequently located in the cerebellum, and is curable via complete resection. - Craniopharyngiomas are benign suprasellar tumors from Rathke's pouch presenting with bitemporal hemianopia and endocrine/hypothalamic dysfunction.
  • Bone Tumors and Metastasis Sites: ((PONC013)): - Osteosarcoma most commonly arises in the metaphysis of long bones near the knee (distal femur, proximal tibia) and characteristically metastasizes early to the lungs (10–20% of patients at diagnosis).
  • Rhabdomyosarcoma Histology: ((PONC019)): Embryonal rhabdomyosarcoma is the most common subtype in children <10 years, occurring primarily in head/neck or genitourinary sites with a relatively favorable prognosis compared to the FOXO1-fused alveolar subtype.
  • Hepatoblastoma Prognosis: ((PONC020)): PRETEXT IV stage with major vascular invasion or extrahepatic spread represents the strongest adverse prognostic indicator, limiting surgical resectability.
  • Langerhans Cell Histiocytosis (LCH) Risk Stratification: ((PONC021)): Multisystem LCH with risk-organ involvement (liver, spleen, and bone marrow) carries the highest risk, demanding systemic chemotherapy, unlike localized unifocal bone or skin lesions which have excellent prognoses. --- ### Late Effects and Cancer Predisposition Syndromes
  • DNA Repair and Chromosomal Instability Syndromes: ((PONC022)): Classic cancer predisposition syndromes driven by defective DNA repair or chromosomal instability include Xeroderma pigmentosum (UV-damaged DNA repair defect), Werner syndrome, and Constitutional mismatch repair deficiency syndrome. Li-Fraumeni syndrome is caused by pathogenic variants in the TP53 tumor-suppressor gene, not classified primarily as a DNA repair disorder.
  • Methotrexate-Associated Leukoencephalopathy: ((PONC023)): Survivors of ALL treated with high-dose/intrathecal methotrexate and CNS radiation are at risk for late cerebral white matter damage presenting with progressive cognitive decline, seizures, and gait ataxia, which is often only partially reversible.
  • Radiation and Chemotherapy-Induced Gonadal Dysfunction: ((PONC024)): Gonadal toxicity depends on pubertal status, sex, and cumulative exposure. Pubertal females face significant ovarian failure risk at radiation doses ≥10 Gy (compared to ≥15 Gy in prepubertal girls), a risk compounded significantly by concurrent alkylating agents.

Pediatric Central Nervous System Tumors

  • Choroid Plexus Carcinoma: ((PONC036)): WHO Grade III malignant intraventricular tumor of infants/young children strongly associated with Li-Fraumeni syndrome caused by germline TP53 pathogenic variants. Craniopharyngioma is a sellar/suprasellar epithelial tumor not linked to TP53 mutations.
  • Craniopharyngiomas: ((PONC037)): WHO Grade I suprasellar tumors presenting with growth failure, delayed puberty, and bitemporal hemianopsia, with solid/cystic components and calcifications. Subtypes: Adamantinomatous craniopharyngioma (ACP) is the pediatric predominant subtype driven by CTNNB1 mutations; Papillary craniopharyngioma (PCP) is adult-predominant and driven by BRAF V600E mutations. Gross total resection is often curative due to non-infiltrative nature.
  • Medulloblastoma: ((((PONC038)) · ((PONC061)))): Most common malignant pediatric brain tumor arising in the midline cerebellum, presenting with signs of raised ICP (headache, vomiting, papilledema) and truncal ataxia. Highly cellular, radiosensitive, and spreads via cerebrospinal fluid pathways.
  • Pilocytic Astrocytoma: ((PONC062)): WHO Grade I glioma commonly supratentorial in older children, classically exhibiting a cystic lesion with an enhancing mural nodule. Carries an excellent prognosis after gross total resection.

Pediatric Leukemia and Lymphoma

  • Precursor B-Cell ALL: ((((PONC043)) · ((PONC045)) · ((PONC046)) · ((CPC047)))): Most common pediatric ALL; immunophenotype positive for CD19, CD10 (CALLA), and TdT. Managed with multi-agent chemotherapy; Blinatumomab is a bispecific T-cell engager (BiTE) binding CD3/CD19 used for relapsed/refractory disease (primary toxicities: cytokine-release syndrome and neurotoxicity). Measurable Residual Disease (MRD) ≥0.01% post-induction is clinically significant, portends higher relapse risk, and mandates treatment intensification. Testicular relapse represents an isolated sanctuary site failure with intermediate prognosis (better than marrow, worse than CNS relapse).
  • Tumor Lysis Syndrome (TLS) & Rasburicase: ((PONC044)): Defined by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. Rasburicase (recombinant urate oxidase) is indicated for rapid enzymatic conversion of uric acid to allantoin (which is much more urine-soluble).
  • Acute Myeloid Leukemia (AML): ((((PONC048)) · ((PONC049)) · ((PONC050)))): Characterized by myeloperoxidase (MPO)-positive blasts, often presenting with gingival hypertrophy (monocytic AML subtype). Acute Promyelocytic Leukemia (APL, AML-M3) features Auer rods and the t(15;17) translocation. Frequently complicated by life-threatening Disseminated Intravascular Coagulation (DIC) due to release of procoagulant substances; treated with all-trans retinoic acid (ATRA) and arsenic trioxide.
  • Chronic Myeloid Leukemia (CML): ((((PONC051)) · ((PONC052)))): Marked leukocytosis with all stages of myeloid maturation, massive splenomegaly, and Philadelphia chromosome (t(9;22)) / BCR-ABL1 fusion. Blast crisis is defined by ≥20% blasts in peripheral blood or bone marrow, signifying aggressive disease progression.
  • Pediatric Non-Hodgkin Lymphoma: ((((PONC055)) · ((PONC056)))): Burkitt lymphoma presents as an acute abdominal mass/obstruction, expressing CD20 and displaying a classical “starry sky” histology. T-cell lymphoblastic lymphoma presents as an anterior mediastinal mass causing Superior Vena Cava (SVC) syndrome.

Renal, Intraocular, and Extracranial Solid Tumors

  • Wilms Tumor Relapse: ((PONC039)): Favorable histology, isolated pulmonary relapse occurring >12 months post-nephrectomy after initial two-drug therapy (vincristine/actinomycin D) without radiotherapy yields a favorable 4-year survival of approximately 80%.
  • Retinoblastoma & RB1 Mutations: ((((PONC040)) · ((PONC059)) · ((PONC060)))): Most common intraocular malignancy presenting with leukocoria ("cat's eye reflex"). Children with positive family history or germline RB1 mutations require regular screening until 7 years of age. Germline mutations confer a high lifelong risk of secondary malignancies, especially osteogenic sarcoma, which is significantly amplified by prior external beam radiation.
  • Neuroblastoma: ((((PONC048)) · ((PONC057)) · ((PONC058)))): Most common extracranial solid tumor of infancy, presenting as an irregular abdominal mass crossing the midline with calcifications and elevated urinary catecholamine metabolites (VMA/HVA). Metastasis to orbital bones produces classic “raccoon eyes” (periorbital ecchymosis). Associated with Opsoclonus-Myoclonus-Ataxia syndrome (immune-mediated paraneoplastic syndrome where neurological sequelae can persist despite complete tumor removal).
  • Hepatoblastoma: ((((PONC042)) · ((CPC066)))): Most common primary hepatic tumor of early childhood (<5 years), presenting with an abdominal mass and markedly elevated alpha-fetoprotein (AFP). Staging requires abdominal CT/MRI and chest CT to evaluate pulmonary metastases.

Bone, Soft Tissue, and Other Malignancies

  • Osteosarcoma: ((PONC063)): Most common primary malignant bone tumor, arising in the metaphysis of long bones (distal femur/proximal tibia) with a radiographic “sunburst” periosteal reaction and Codman’s triangle.
  • Ewing Sarcoma: ((PONC064)): Arises in the diaphysis of long/flat bones, showing an “onion-skin” layered periosteal reaction and small round blue cells with strong membranous CD99 positivity.
  • Orbital Rhabdomyosarcoma: ((PONC065)): Rapidly progressive proptosis; biopsy shows small round blue cells positive for muscle markers desmin, myogenin, and MyoD1.
  • Intracranial Germ Cell Tumors: ((PONC041)): Alpha-fetoprotein (AFP) is physiologically elevated in infancy, declining to adult levels by ~8 months; thus, values in infants must be interpreted using age-adjusted reference values. Both serum and CSF must be assayed for AFP and $\beta$-hCG to direct diagnosis and management.
  • Langerhans Cell Histiocytosis (LCH): ((PONC067)): Multisystem presentation featuring lytic bone lesions (temporal bone), skin rash, and ear involvement. Pathology shows coffee-bean nuclei and immunopositivity for CD1a and langerin (CD207).
  • Sacrococcygeal Teratoma: ((PONC068)): Most common extragonadal germ cell tumor of infancy; mixed cystic-solid sacrococcygeal mass with markedly elevated AFP pointing toward malignant yolk sac transformation.
  • Cancer Predisposition Syndromes: ((((PONC069)) · ((PONC070)))):
  • Li-Fraumeni Syndrome: : TP53 mutations associated with brain tumors, osteosarcoma, breast cancer, and rhabdomyosarcoma.
  • Bloom Syndrome: : DNA repair defect with chromosomal instability presenting with marked growth failure, recurrent infections, and photosensitive telangiectatic facial erythema.

Pediatric Hematology-Oncology: Leukemias, Lymphomas, and Chemotherapy Toxicity

  • Acute Lymphoblastic Leukemia Translocations: ((PONC071)): ETV6::RUNX1 fusion is caused by t(12;21), representing oncogene activation via chimeric protein formation in childhood ALL. Distinguish from t(9;22) (BCR::ABL1, seen in CML/ALL) and t(8;14) (MYC::IGH, seen in Burkitt lymphoma).
  • WAGR Syndrome: ((PONC072)): Characterized by Wilms tumor, aniridia, genitourinary anomalies, and developmental delay, caused by chromosomal deletion of 11p13 involving the WT1 gene. Distinguish from 11p15 imprinting abnormalities seen in Beckwith-Wiedemann syndrome.
  • PTEN Hamartoma Tumor Syndromes: ((PONC073)): Includes Cowden and Bannayan-Riley-Ruvalcaba syndromes linked to the PTEN/PI3K-AKT pathway, classically predisposing to thyroid carcinoma, breast, and renal cancers. Distinguish from retinoblastoma (RB1, 13q14) and medulloblastoma associated with Gorlin-Goltz syndrome (PTCH1/SUFU).
  • High-Risk Neuroblastoma Immunotherapy: ((PONC074)): Treated with Dinutuximab, a monoclonal antibody directed against GD2 (disialoganglioside) heavily expressed on neuroblastoma cells. Distinguish from Brentuximab (CD30, Hodgkin lymphoma), Blinatumomab (CD19, leukemia), and Bevacizumab (VEGF-R, glioma).
  • Neurofibromatosis Type 1 Targeted Therapy: ((PONC075)): Plexiform neurofibromas in NF1 are treated with Selumetinib, a selective MAPK/MEK inhibitor. Distinguish from monoclonal antibodies Rituximab (CD20) and Brentuximab (CD30).
  • Vincristine Toxicity Profile: ((PONC076)): Causes severe peripheral neuropathy, jaw pain, constipation, ileus, SIADH, and local cellulitis upon extravasation. Pathognomonic clue: Causes minimal to no myelosuppression compared to other cytotoxic agents.
  • Carmustine Delayed Toxicity: ((PONC077)): Nitrosourea causing delayed bone marrow suppression (weeks post-exposure) and progressive pulmonary fibrosis.
  • 6-Mercaptopurine Mechanism: ((PONC078)): Purine analog utilized in ALL maintenance that inhibits purine synthesis and incorporates into nucleic acids via activation through the purine salvage pathway.
  • Ifosfamide Toxicity and Prevention: ((PONC079)): Alkylating agent complicated by hemorrhagic cystitis, which is prevented by co-administration of mesna.
  • Radiation Dermatitis: ((PONC080)): Dermatitis is the most common general adverse effect of radiation therapy due to the skin's inclusion in the radiation field.
  • CAR-T Cell Therapy and Cytokine Release Syndrome: ((PONC081)): High-grade fevers, hypotension, hypoxia, and neurotoxicity occurring post-CAR-T due to rapid immune activation mediated by Interleukin-6 (IL-6). Mandatory treatment: Tocilizumab (IL-6 receptor antagonist). High pretreatment leukemic burden increases severity.
  • Late Ototoxicity: Cisplatin + Radiation: ((PONC082)): Bilateral high-frequency sensorineural hearing loss results from cumulative dose-dependent cochlear injury (highest risk at ≥360 mg/m²) combined with cranial radiation affecting the auditory apparatus at >30 Gy (additive ototoxicity).
  • Chemotherapy-Induced Pulmonary Fibrosis: ((PONC083)): Restrictive lung disease caused by bleomycin, busulfan, and nitrosoureas (carmustine, lomustine). Note: Cisplatin does not cause pulmonary fibrosis; its late toxicities are nephrotoxicity and ototoxicity.
  • Bispecific T-Cell Engagers (BiTEs): ((PONC084)): Blinatumomab simultaneously binds CD3 on T-cells and CD19 on B-ALL blasts, crucial for eradicating persistent measurable residual disease (MRD). Distinguish from Inotuzumab ozogamicin (antibody-drug conjugate targeting CD22).
  • Inherited AML Predisposition Syndromes: ((PONC085)): Bloom syndrome, Kostmann syndrome, and Neurofibromatosis type 1 increase childhood AML risk. Note: Patau syndrome (Trisomy 13) is not an established predisposition syndrome for pediatric AML.
  • Hyperleukocytosis in CML: ((PONC086)): Symptomatic hyperleukocytosis (headache, visual blurring, painful splenomegaly) is managed acutely with hydroxyurea for short-term cytoreduction while awaiting definitive tyrosine kinase inhibitor (TKI) efficacy.
  • High-Risk AML Post-Remission Strategy: ((PONC087)): Adverse cytogenetics (e.g., monosomy 7) combined with persistent measurable residual disease (MRD) mandate allogeneic stem cell transplantation in first remission.
  • ALL Risk Stratification Override by MRD: ((PONC088)): Favorable NCI criteria and hyperdiploidy are overridden by day-29 MRD exceeding 0.01%, which independently warrants treatment intensification.
  • CNS Relapse Prevention in ALL: ((PONC089)): The dramatic reduction of historical CNS relapse rates (<5%) is primarily driven by consolidation therapy utilizing repeated intrathecal chemotherapy combined with intensive systemic chemotherapy.
  • Juvenile Myelomonocytic Leukemia (JMML) Drivers: ((PONC090)): Driven by RAS pathway alterations (PTPN11, NF1, CBL, KRAS, NRAS). Note: RUNX1 is not a characteristic JMML gene (more typical of AML/FPDMM).
  • Infant AML vs. ALL Presentation: ((PONC091)): Infant AML commonly features extramedullary disease like violaceous skin nodules (leukemia cutis) and CNS involvement (often acute myelomonocytic leukemia). Infant ALL presents as KMT2A-rearranged (e.g., t(4;11)) CD10-negative pro-B disease. ---

Lymphomas and Staging

  • Hodgkin Lymphoma Stage III: ((PONC092)): Defined by lymph node involvement on both sides of the diaphragm, or nodal disease above the diaphragm combined with splenic involvement (without noncontiguous extranodal disease).
  • Refractory Hodgkin Lymphoma Targeted Therapy: ((((PONC093)) · ((PONC094)))):
  • Brentuximab vedotin: : Antibody-drug conjugate targeting CD30 on Reed-Sternberg cells, delivering the antimitotic payload monomethyl auristatin E.
  • Nivolumab / Pembrolizumab: : Immune checkpoint inhibitors targeting PD-1 to reverse T-cell exhaustion.
  • Burkitt Lymphoma Frontline Therapy: ((((PONC095)) · ((PLAT102)))): Unresected intermediate-risk Burkitt lymphoma (Group B) is treated with intensive short-course chemotherapy plus Rituximab (anti-CD20 monoclonal antibody), significantly improving EFS and OS. Maintenance therapy is not used.
  • Anaplastic Large Cell Lymphoma (ALCL) Target: ((PONC096)): The t(2;5) translocation generates the NPM-ALK fusion protein, specifically targeted by oral TKI Crizotinib.
  • Lymphoblastic Lymphoma Presentation: ((PONC097)): Precursor T-cell malignancy presenting with a symptomatic anterior mediastinal mass (cough, dyspnea, superior vena cava syndrome) and a high propensity for bone marrow and CNS dissemination.
  • IPNHLSS Staging Nuances: ((((PONC098)) · ((PONC099)))): - Primary gastrointestinal tumors (e.g., ileocecal) with regional mesenteric lymph node involvement are classified as Stage II if completely resectable. - Bone marrow involvement detection methods: BMm (morphology), BMi (immunohistochemistry/flow cytometry), BMc (cytogenetics/FISH), and BMmol (molecular/PCR).
  • Burkitt Lymphoma Response Criteria (IPNHLRC): ((PONC100)): Persistent radiographic residual masses with no morphologic, marrow, or CSF evidence of active lymphoma are classified as Complete response, unconfirmed (CRu).
  • Tumor Lysis Syndrome Prophylaxis: ((PONC101)): High-risk Burkitt lymphoma requires hydration and rasburicase (urate oxidase). Contraindication: Glucose-6-phosphate dehydrogenase (G6PD) deficiency (triggers severe hemolysis/methemoglobinemia).
  • T-Cell Lymphoblastic Lymphoma Enhancement: ((PONC103)): Upfront ALL-type regimens are increasingly enhanced with Nelarabine, a purine analog offering selective T-lymphocyte toxicity and reduced CNS relapse.
  • Relapsed B-Cell NHL Inhibitors: ((PONC104)): Idelalisib selectively inhibits the delta isoform of phosphoinositide 3-kinase (PI3K-delta) to disrupt B-cell survival signaling.
  • Turcot Syndrome Molecular Associations: ((PONC105)): Medulloblastoma associated with a 5q21 mutation points to APC gene alterations, whereas glioblastomas in Turcot syndrome stem from DNA mismatch repair gene defects (hMLH1, hPMS2).

Pediatric Neuro-Oncology & Posterior Fossa Tumors

  • Ependymoma: ((PONC106)): Arises classically from the fourth ventricle with hallmark lateral extension toward the cerebellopontine angle, causing progressive raised ICP, unsteadiness, diplopia, and facial asymmetry. Distractor pearl: Medulloblastoma typically presents over a shorter duration with midline truncal ataxia and a solid midline cerebellar vermis mass.
  • Medulloblastoma in Infants <3 Years: ((PONC107)): Avoid conventional craniospinal irradiation due to profound permanent neurocognitive, endocrine, and developmental sequelae (microcephaly, growth failure, lower IQ). Standard management for localized M0 disease utilizes high-dose systemic chemotherapy followed by autologous peripheral stem cell reinfusion to defer radiation. ---

Neuroblastoma & Associated Syndromes

  • Kerner-Morrison Syndrome: ((PONC108)): Paraneoplastic presentation of neuroblastoma caused by tumor secretion of vasoactive intestinal peptide (VIP), leading to profuse secretory watery diarrhea, dehydration, and failure to thrive; associated with biologically favorable tumors. Distractor pearls: Pepper syndrome = massive liver/skin metastases in infants; Hutchinson syndrome = skull bone/orbital metastases causing raccoon eyes.
  • Familial Pheochromocytoma-Paraganglioma Syndrome: ((PONC109)): Autosomal dominant disorder linked to germline pathogenic variants in MAX (and other susceptibility genes like SDH), predisposing to neural crest–derived tumors including neuroblastoma, pheochromocytoma, and paraganglioma. Distractor pearl: PHOX2B mutations associate with congenital central hypoventilation syndrome (Ondine curse) and neuroblastoma.
  • Stage 4S Neuroblastoma: ((PONC110)): Defined as a localized primary tumor (stage 1/2A/2B) in an infant <1 year old with metastases restricted strictly to the liver, skin, and/or minimal bone marrow (<10%). Displays a unique propensity for spontaneous regression with survival exceeding 80–90%. Crucial rule: Any cortical bone involvement or extensive marrow replacement upgrades the disease to standard Stage 4.
  • High-Risk Neuroblastoma Management & Immunotherapy: ((((PONC111)) · ((PONC112)))): Marked by bone/marrow metastases and segmental chromosomal aberrations (e.g., MYCN amplification, 1p/11q deletion). Requires intensive multimodal therapy: induction chemotherapy, surgical resection, focal radiotherapy, and myeloablative consolidation with autologous stem cell rescue. Post-transplant maintenance utilizes isotretinoin (13-cis-retinoic acid) for cellular differentiation combined with dinutuximab (anti-GD2 monoclonal antibody), which targets the GD2 disialoganglioside to improve 2-year event-free survival significantly. ---

Wilms Tumor & Renal Malignancies

  • Denys-Drash Syndrome: ((PONC113)): Wilms tumor predisposition syndrome caused by WT1 pathogenic variants (exon 8 or 9). Characterized by the classic triad of ambiguous genitalia / disordered sexual development, diffuse mesangial sclerosis (early renal failure), and >75% risk of Wilms tumor. Distractor pearl: Frasier syndrome involves WT1 intron 9 splice-site variants presenting with gonadoblastoma and focal segmental glomerulosclerosis.
  • Wilms Tumor Molecular Risk Markers: ((PONC114)): Gain of chromosome 1q is the strongest molecular predictor of inferior survival even in histologically favorable tumors. Combined loss of heterozygosity (LOH) at 1p and 16q indicates an increased risk of relapse.
  • Wilms Tumor Staging (COG Criteria): ((PONC115)): Stage II disease is defined by tumor extending beyond the kidney but completely resected with negative margins and negative lymph nodes (capsular penetration or renal sinus vessel invasion are permitted if completely excised). Crucial rule: Microscopic residual tumor, intraoperative tumor spillage, or regional nodal involvement instantly upgrades the tumor to Stage III.
  • Clear Cell Sarcoma of the Kidney: ((PONC116)): A distinct renal malignancy with a characteristic metastatic tropism for bone and brain. Staging mandates specialized imaging including a bone scan and brain CT/MRI, differing from classic Wilms tumor which preferentially metastasizes to the lungs.
  • Very Low-Risk Wilms Tumor: ((PONC117)): Unilateral favorable-histology Wilms tumor in children <2 years old with stage I disease and tumor weight <550 g. Managed successfully with nephrectomy alone, completely omitting adjuvant chemotherapy to avoid unnecessary toxicity.
  • Stage IV Wilms Tumor Treatment Escalation: ((PONC118)): Persistent pulmonary metastases after 6 weeks of standard DD4A (vincristine, doxorubicin, actinomycin D) require treatment intensification to Regimen M (adding cyclophosphamide and etoposide) alongside mandatory lung irradiation.
  • Pediatric Renal Cell Carcinoma: ((PONC119)): Most frequent renal malignancy in the second decade of life. The predominant pediatric subtype is translocation-associated RCC, classically characterized by TFE3 (Xp11.2) or TFEB (6p21) gene translocations. Localized cases are treated primarily with nephrectomy. ---

Bone & Soft-Tissue Sarcomas

  • Botryoid Rhabdomyosarcoma: ((((PONC120)) · ((C121)))): Embryonal rhabdomyosarcoma variant arising beneath mucosal surfaces of hollow organs (vagina, bladder), presenting as a painless, polypoidal, grapelike mass protruding through the vaginal introitus in young girls. Diagnostic group: Part of small, round, blue cell tumors (along with neuroblastoma, Ewing sarcoma, and NHL), diagnosed via desmin and myogenin positivity.
  • Parosteal Osteosarcoma: ((((PONC122)) · ((C123)))): A low-grade surface osteosarcoma typically arising from the posterior distal femur. Radiographically manifests as a well-differentiated surface bone tumor without medullary cavity invasion. Exhibits low metastatic potential; complete surgical resection alone is curative (unlike conventional high-grade osteosarcomas which require aggressive multiagent chemotherapy). Parosteal is not a subtype of conventional high-grade osteosarcoma (which comprise osteoblastic, chondroblastic, fibroblastic, and telangiectatic variants).
  • Ewing Sarcoma Dose-Density: ((PONC124)): Treated with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide. Administering chemotherapy every 14 days (dose-dense) rather than every 21 days significantly improves event-free survival by preventing the repopulation of residual tumor cells between cycles.
  • Osteochondroma: ((PONC125)): Benign cartilage-capped bone tumor occurring at long-bone metaphyses (distal femur). Hallmark radiographic finding: bony projection pointing away from the adjacent joint, with continuous cortex and medullary cavity continuity with the parent bone.
  • Maffucci Syndrome: ((PONC126)): Characterized by multiple enchondromas associated with soft-tissue vascular malformations (hemangiomas), limb-length discrepancies, and a high risk of malignant transformation (chondrosarcoma). Distinguishable from Ollier disease, which features multiple enchondromas without vascular lesions. ---

Retinoblastoma & Germ Cell Tumors

  • Bilateral Retinoblastoma in Infants: ((PONC127)): In very young infants with large bilateral tumors, preservation of vision and avoidance of high-risk ophthalmic intraarterial complications are prioritized via systemic chemoreduction (carboplatin, vincristine, etoposide) followed by aggressive focal therapy (laser/cryotherapy). Enucleation is restricted to blinded or non-salvageable eyes.
  • Pediatric Germ Cell Tumor Markers: ((((PONC128)) · ((C129)))):
  • Yolk Sac Tumor (Endodermal Sinus Tumor):: Most common malignant GCT in children; characteristically secretes alpha-fetoprotein (AFP) with normal $\beta$-hCG.
  • Embryonal Carcinoma:: Aggressive GCT that uniquely secretes both AFP and $\beta$-hCG elevated simultaneously. ---

Metabolic Disorders & Histiocytic Disorders

  • Glycogen Storage Disease Type I (GSD I): ((PONC130)): Predisposes to the development of hepatocellular carcinoma in a noncirrhotic liver, driven by chronic metabolic instability, marked hepatomegaly, and the proliferation of hepatic adenomas prone to malignant transformation.
  • Langerhans Cell Histiocytosis (LCH): ((((PONC131)) · ((C132)))): Clonal myeloid neoplasm defined by lesional cells expressing CD1a and CD207 (langerin). Pathogenesis is driven by the somatic BRAF V600E mutation (activating the MAPK pathway). Disseminated multisystem disease with risk-organ involvement (hepatosplenomegaly, cytopenias) is treated front-line with vinblastine and corticosteroids.
  • Erdheim-Chester Disease: ((PONC133)): Non-Langerhans cell histiocytosis presenting with symmetric long-bone lower-limb pain, exophthalmos, xanthelasma, diabetes insipidus, and hallmark imaging features: perinephric infiltration ("hairy kidney") and circumferential periaortic sheathing ("coated aorta"). ---

Hematologic Malignancies

  • B-Cell Acute Lymphoblastic Leukemia (B-ALL): ((PONC134)): Bone marrow aspirate reveals a monotonous population of lymphoblasts with a high nucleus-to-cytoplasm ratio, scant cytoplasm, fine immature chromatin, and inconspicuous nucleoli.
  • Acute Promyelocytic Leukemia (APL / AML-M3): ((PONC135)): Characterized morphologically by malignant promyelocytes containing bundles of Auer rods ("faggot cells"). Mandatory action: Requires emergency initiation of ATRA upon identification to avert fatal disseminated intravascular coagulation (DIC).
  • AML-M4Eo (Myelomonocytic with Eosinophilia): ((((PONC136)) · ((C137)))): Pathognomonic cytogenetic abnormality: $\text{inv}(16)(p13q22)$. Associated with abnormal eosinophils in the marrow and represents a favorable prognostic risk category.
  • Chronic Myeloid Leukemia (CML): ((((PONC138)) · ((C139)))): Peripheral blood smear reveals a full spectrum of granulocytic maturation ("myelocyte bulge": myelocytes, metamyelocytes, bands, neutrophils) with absolute basophilia and low blast counts in the chronic phase. Driven by the Philadelphia chromosome ($t(9;22)$) producing the BCR-ABL1 fusion tyrosine kinase, specifically targeted by imatinib.
  • Hodgkin Lymphoma: ((PONC140)): Diagnostic hallmark is the presence of Reed–Sternberg cells: large, multinucleated (or binucleated) B-cell lineage cells displaying prominent inclusion-like nucleoli ("owl's eye" appearance).

Hematological Malignancies & Lymphomas

  • Burkitt Lymphoma Histology & Immunophenotype: ((((PONC141)) · ((PONC150)))): Pathognomonic “starry sky” appearance driven by rapidly proliferating lymphoid cells interspersed with tingible-body macrophages. Neoplastic cells are mature B-cells strongly expressing CD20. Distractors: T-cell lymphoblastic lymphoma shows blasts mimicking ALL; anaplastic large cell lymphoma (ALCL) shows pleomorphic cells with kidney-shaped nuclei that are CD30-positive and frequently ALK-positive.
  • Hodgkin Lymphoma Variants & Hallmark Cells: ((((PONC146)) · ((PONC147)))): Classical Hodgkin lymphoma features classic Reed-Sternberg cells (large binucleated/multinucleated cells with prominent eosinophilic nucleoli and a mirror-image appearance). Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) features L and H (“popcorn”) cells with folded, multilobulated nuclei, representing a distinct immunophenotype from classical HL.
  • Hodgkin Lymphoma Prognostic Markers & Staging: ((((PONC148)) · ((PONC149)))): Abundant CD68-positive tumor-associated macrophages within the microenvironment predict treatment failure and adverse prognosis. Interim response assessment via PET-CT utilizes the Deauville 5-point scale, where a score of 4 denotes residual metabolic activity moderately greater than liver uptake. Distractors: A score of 1-3 indicates favorable response, whereas a score of 5 represents markedly increased uptake or new lesions.
  • Diffuse Large B-Cell Lymphoma (DLBCL): ((PONC151)): Displays large atypical lymphoid cells featuring abundant cytoplasm, vesicular nuclei, and prominent nucleoli, expressing mature B-cell markers (CD20, CD22).
  • Non-Hodgkin vs. Hodgkin Lymphoma Patterns: ((PONC169)): Non-Hodgkin lymphoma (NHL) presents with rapid progression, non-contiguous (discontinuous) nodal spread, abdominal bulky disease, and a high frequency of central nervous system (CNS) or bone marrow involvement at presentation. Distractors: Hodgkin lymphoma spreads contiguously and rarely presents with primary CNS disease.
  • Acute Lymphoblastic Leukemia (ALL) Classification & Markers: ((((PONC165)) · ((CPC166)))): The FAB L3 subtype represents mature B-cell ALL (Burkitt-type), showing large homogeneous blasts with intensely basophilic cytoplasm and prominent cytoplasmic vacuolation. Precursor B-cell ALL characteristically expresses CD19 and CD10, correlating with a favorable prognosis. Distractors: CD10-negative precursor B-cell ALL is linked to KMT2A (MLL) rearrangements and poor outcomes.
  • ALL Cytogenetic Prognosis: ((PONC172)): BCR-ABL1 [t(9;22)] (Philadelphia chromosome) confers very high-risk disease and an adverse prognosis, requiring intensified therapy and tyrosine kinase inhibitors. Distractors: Hyperdiploidy (>50 chromosomes) and trisomy 4 and 10 denote favorable prognoses.
  • Acute Promyelocytic Leukemia (APL / AML-M3): ((PONC167)): Characterized by severe disseminated intravascular coagulation (DIC) due to the release of procoagulant factors from abnormal promyelocytes, leading to prolonged PT/aPTT, low fibrinogen, and elevated D-dimers. Mandatory Action: Promptly initiate all-trans retinoic acid (ATRA) upon clinical suspicion prior to cytogenetic confirmation.
  • Juvenile Myelomonocytic Leukemia (JMML): ((PONC168)): A mixed myelodysplastic/myeloproliferative neoplasm presenting before 5 years of age with hepatosplenomegaly, marked monocytosis, elevated fetal hemoglobin (HbF), and Philadelphia chromosome-negativity. The hallmark cytogenetic finding is monosomy 7 (present in ~30%).
  • Childhood AML Risk Stratification: ((PONC174)): BCR-ABL1 [t(9;22)] and KMT2A rearrangements are classified as adverse-risk genetic lesions requiring intensive therapy and consideration of hematopoietic stem cell transplant. Distractors: inv(16) and biallelic CEBPA mutations signify favorable-risk disease.
  • Tumor Lysis Syndrome (TLS): ((PONC175)): Manifests with acute uric acid nephropathy, oliguria, hyperkalemia, hyperphosphatemia, hypocalcemia, and markedly elevated uric acid following induction chemotherapy in high-grade lymphomas. Mandatory Action: Aggressive intravenous hydration combined with rasburicase (which rapidly converts uric acid to soluble allantoin).

Solid Tumors & Central Nervous System (CNS) Tumors

  • Neuroblastoma Histology & Imaging: ((((PONC142)) · ((PONC155)) · ((CPC156)) · ((PONC162)))): Characterized by Homer Wright rosettes (neuroblasts arranged around a central fibrillary core of neuropil without a true lumen). Classic clinical clues include periorbital ecchymosis with proptosis (orbital metastasis). Diagnosis can be confirmed without primary tumor biopsy if bone marrow shows small round blue cells alongside elevated urinary VMA or HVA. ¹²³I-MIBG scintigraphy is the imaging modality of choice for specific staging and metastatic evaluation of neural crest tumors.
  • Retinoblastoma Genetics & Presentation: ((((PONC143)) · ((PONC170)))): Classically appears as a cream-colored intraocular retinal mass with prominent feeder vessels and intraocular calcifications. Bilateral, multifocal retinal tumors strongly favor hereditary retinoblastoma (germline RB1 mutation), which carries an elevated lifetime risk of second primary malignancies.
  • Hepatoblastoma: ((PONC144)): Presents as a large, well-defined hepatic mass with heterogeneous enhancement, calcifications, and markedly elevated alpha-fetoprotein (AFP) in a young child.
  • Langerhans Cell Histiocytosis (LCH): ((PONC145)): A clonal dendritic cell neoplasm presenting with lytic skull lesions. Diagnostic immunophenotype requires expression of both CD1a and CD207 (langerin), the latter correlating with diagnostic ultrastructural Birbeck granules.
  • Pineal Germ Cell Tumors: ((PONC152)): Pineal mass presenting with early-onset (precocious) puberty and obstructive hydrocephalus via ventricular enlargement. Diagnostic workup requires measuring serum and CSF β-hCG and α-fetoprotein.
  • Pediatric Brain Tumors & Syndromes: ((((PONC153)) · ((PONC154)) · ((PONC171)))): - Cerebellar pilocytic astrocytoma (WHO Grade I): Circumscribed cystic cerebellar mass with an enhancing mural nodule; complete surgical excision achieves long-term survival nearing 80–100%. - Thalamic high-grade astrocytoma: Infiltrative intra-axial mass in an adolescent causing contralateral weakness, carrying a poor prognosis due to inoperability. - Syndrome associations: Neurofibromatosis type 1 (optic glioma); Tuberous sclerosis (subependymal giant cell astrocytoma / SEGA); Turcot syndrome (medulloblastoma/glioma); Li-Fraumeni syndrome is classically linked to choroid plexus carcinoma (not medulloblastoma).
  • Wilms Tumor Staging: ((PONC157)): Bilateral renal masses at diagnosis are classified as Stage V Wilms tumor, requiring renal-sparing preoperative chemotherapy and partial nephrectomies.
  • Osteosarcoma Management: ((((PONC158)) · ((PONC163)))): Aggressive metaphyseal bone tumor of the distal femur showing a sunburst periosteal reaction. Standard protocol dictates preoperative MAP chemotherapy (methotrexate, doxorubicin, cisplatin), followed by complete surgical resection and postoperative chemotherapy. Routine bone marrow examination is not indicated for initial staging (unlike Ewing sarcoma or non-Hodgkin lymphoma).
  • Benign Childhood Bone Lesions: ((((PONC159)) · ((PONC160)))): - Nonossifying fibroma: Asymptomatic, well-defined eccentric radiolucent metaphyseal lesion with a thin sclerotic rim; requires observation only. - Subungual exostosis: Osteochondromatous outgrowth beneath the nailbed causing pain and nail distortion; treated via complete surgical excision and nailbed repair.
  • Hemophagocytic Lymphohistiocytosis (HLH) Criteria: ((PONC173)): HLH-2004 diagnostic cutoffs include fasting triglycerides \>265 mg/dL (>3 mmol/L), fibrinogen <1.5 g/L, ferritin >500 µg/L, and soluble CD25 (sIL-2R) >2400 U/mL.
  • Cancer Predisposition Syndromes & Leukemia Risk: ((PONC164)): Fanconi anemia, Shwachman-Diamond syndrome, Neurofibromatosis type 1, and Down syndrome strongly predispose to childhood leukemia. Distractors: Beckwith-Wiedemann syndrome is an overgrowth disorder predisposing exclusively to embryonic solid tumors (Wilms tumor, hepatoblastoma, neuroblastoma), not leukemia.

Pediatric Oncologic Emergencies

  • Tumor Lysis Syndrome (TLS): ((PONC176)): Results from rapid destruction of malignant cells (e.g., in Burkitt lymphoma), releasing intracellular components into the circulation. Classic metabolic hallmarks include hyperkalemia, hyperphosphatemia, hyperuricemia, and secondary hypocalcemia (driven by calcium-phosphate precipitation). Hyponatremia is not classically associated with TLS; its presence mandates investigation for alternate etiologies like SIADH or free water excess.
  • Superior Vena Cava (SVC) Syndrome: ((PONC177)): Caused by extrinsic compression of the superior vena cava, commonly by an anterior mediastinal mass (frequently seen in T-cell acute lymphoblastic leukemia or lymphoma). Hallmark clinical features comprise progressive dyspnea, facial and neck edema, distended neck veins, plethora, and cyanosis, requiring immediate oncologic intervention.